BVXV News and Press, BiondVax Pharmaceuticals Ltd. From 03/24/23

BiondVax (NASDAQ: BVXV) is a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases. “BiondVax is seeing convincingly positive outcomes for preventing and arrest...

Asthma is a respiratory condition that affects 26.5 million Americans and around 300 million people worldwide. It is characterized by chronic inflammation in the lung airways that results in chest tightness, wheezing, shortness of breath or coughing. This tightening usually occurs when the ...

The Japanese government recently announced that the coronavirus will be categorized as a common infectious disease on May 8, 2023. As a result, patients diagnosed with the communicable disease will have to cover medical expenses on their own. In the wake of the coronavirus pandemic in 2020,...

BiondVax (NASDAQ: BVXV) , a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, today announced that its CEO Amir Reichman will be presenting in-person at the 17th...

JERUSALEM, March 16, 2023 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals Ltd . (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infe...

Asthma is a respiratory disease caused by chronic inflammation in the lung airways and is characterized by shortness of breath, chest tightness, wheezing and coughing. It affects an estimated 8.3% of Americans (26.5 million) with 6.1 million being children and 20.4 million being adults. For t...

The COVID-19 pandemic showed us just how quickly an infectious disease can spread in our modern interconnected world. Just a few months after the disease was first discovered in Wuhan, China, it had spread to most continents and shut down dozens of economies across the world. Even though we are...

BiondVax Pharmaceuticals (NASDAQ: BVXV) , a biotech company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, is spotlighted in a recent episode of the “Test. Optimize. Scale.&#...

LOS ANGELES, March 03, 2023 (GLOBE NEWSWIRE) -- via InvestorWire -- IBN , a multifaceted financial news and publishing company for private and public entities, today announces that Amir Reichman, CEO of biotechnology company BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) , recently appe...

BiondVax (NASDAQ: BVXV) , a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products, is working on changing the grim reality caused by the evolution of COVID-19. “The company’s leading inhaled nanosized antibody (‘N...